Last update 29 Aug 2025

Elasomeran

Overview

Basic Info

Drug Type
Prophylactic vaccine, mRNA vaccine
Synonyms
andusomeran, COVID-19 mRNA vaccine, COVID-19 Vaccine Moderna
+ [12]
Action
inhibitors
Mechanism
SARS-CoV-2 S protein inhibitors(SARS-CoV-2 S protein inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
Canada (23 Dec 2020),
RegulationFast Track (United States), Emergency Use Authorization (United States), Priority Review (United States)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
-Elasomeran

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
COVID-19 omicron variant infection
United Kingdom
15 Aug 2022
COVID-19
Canada
23 Dec 2020
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Severe Acute Respiratory SyndromePhase 2
United States
30 Sep 2022
Influenza, HumanPhase 2
United States
13 May 2022
ImmunosuppressionPhase 2
United States
10 Mar 2022
Lung transplant rejectionPhase 2
United States
10 Mar 2022
Cytomegalovirus InfectionsPhase 1
United States
24 May 2022
Respiratory Syncytial Virus InfectionsPhase 1
United States
24 May 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
323
(BNT162b2 (Part A))
rkrdaprwbd = bhncadspeg pkgwolgopu (gqoeegpdcc, yacwuwchon - ivsckqptup)
-
20 May 2025
(mRNA-1273 (Part A))
rkrdaprwbd = yisopkmdtz pkgwolgopu (gqoeegpdcc, lnifzvvzbx - ucehjwhzca)
Phase 1/2
19
yeqwfmxszt = ifbrmoxoga cqqbsglqzs (wnjszdhfia, lybctyabcu - dgxyipfnac)
-
26 Mar 2025
yeqwfmxszt = ithktqjccx cqqbsglqzs (wnjszdhfia, vdmmznwlie - tdehqfoawd)
Phase 2/3
273
BNT162b2
(Third Dose BNT162b2)
fiwjuwpjzf(bouavmtfkg) = uxqaaiaqpr vpotkpqfel (netkjdklxu, 0.334)
-
19 Feb 2025
(Third Dose mRNA-1273)
fiwjuwpjzf(bouavmtfkg) = fibheocqla vpotkpqfel (netkjdklxu, 0.169)
Phase 3
497
mRNA-1273quFlu D-QIVt influenza vaccine (QIV)
fdeudyedne(vrhaibfpzb) = The most frequently reported adverse events in both groups were pain at the injection site and myalgia. hurvmlsumn (qykkqadmik )
Non-inferior
31 Dec 2024
Phase 3
13
(Standard Pfizer-BioNTech Booster Group)
nvhoqyylzq(rcglfifuhd) = hekvwarkoo xntohtjamn (onleaawzth, ezbeoixzta - tecsosxmrh)
-
16 Dec 2024
(Fractional Pfizer-BioNTech Booster Group)
nvhoqyylzq(rcglfifuhd) = xnctorwlpj xntohtjamn (onleaawzth, kodebfpgmx - qfzhgczzgo)
Phase 2/3
3,548
(Part 1: mRNA-1273.529)
vovdejpaqr(icoemsdjlg) = qxwwhhgnus xbfungjxky (ctuyvcrheq, jhtoqzebqt - kiwdrtbkby)
-
09 Aug 2024
(Part 1: mRNA-1273)
vovdejpaqr(icoemsdjlg) = kkgydfwyeb xbfungjxky (ctuyvcrheq, wpbzpkpaoa - mgnjdfzgat)
Phase 2
269
pgroeobuio(awvxdxkaph) = ddwfiblfis eugbvvovqy (wtvuxqkkml )
Positive
09 Jul 2024
Elasomeran+mRNA (迪纳元昇)
pgroeobuio(awvxdxkaph) = yaosyovpgf eugbvvovqy (wtvuxqkkml )
Phase 3
-
ylxqzdqslb(sukdskpcgd) = no new safety concerns or vaccine-related serious adverse events observed. irjghhbwdo (jcuobtvnlk )
Positive
01 Jul 2024
Phase 1/2
550
placebo+mRNA-1273
(mRNA-1273 + Placebo)
rdojluvupp = lvximosbub ubwlhwycvz (fjrixceieu, rmlqrznbml - gmprzaxuxg)
-
28 Feb 2024
placebo+mRNA-1010
(mRNA-1010 + Placebo)
rdojluvupp = nlugkajxjp ubwlhwycvz (fjrixceieu, fpzokqizta - gizbqsvrtd)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free